TRAPPC2: A Potential Drug Target and Biomarker (G6399)

Target Name: TRAPPC2

NCBI ID: G6399

TRAPPC2

TRAPPC2: A Potential Drug Target and Biomarker

TRAPPC2, also known as hYP38334, is a protein that is expressed in various tissues and cell types in the body. Its full name is trastuzumab-associated protein P2 (TAP2), and it is a member of the tyrosine kinase family 2 (TKTK2) gene. TRAPPC2 is known for its role in cell signaling and has been implicated in various diseases, including cancer. As a potential drug target and biomarker, TRAPPC2 is attracting a lot of attention in the scientific community.

TRAPPC2 is a 21-kDa protein that is expressed in various tissues, including the brain, heart, liver, and gastrointestinal tract. It is a key regulator of cell signaling, particularly in the TKTK2 pathway. The TKTK2 pathway is a highly conserved gene family that is involved in the regulation of cell growth, differentiation, and survival. This pathway is also known as the PDGF signaling pathway, and it is involved in the development and maintenance of various tissues in the body.

TRAPPC2 is a key regulator of the TKTK2 pathway. It is a negative regulator of the TKTK2 kinase, which is a protein that is involved in the regulation of cell signaling. The TKTK2 kinase is a G protein-coupled receptor (GPCR), and it is involved in the regulation of various cellular processes, including cell growth, differentiation, and survival. The TKTK2 pathway is also involved in the regulation of angiogenesis, which is the process of the formation of new blood vessels.

TRAPPC2 is involved in the regulation of several downstream targets of the TKTK2 pathway, including the conscientious cell proliferation and differentiation (SCOD), apoptosis (CDKK), vascular endothelial growth factor (VEGF), and basal cell growth factor (BCGF). These downstream targets are important regulators of cell signaling and are involved in the regulation of various cellular processes, including cell growth, differentiation, and survival.

TRAPPC2 is also involved in the regulation of the TKTK2 pathway in the regulation of cellular adhesion. The TKTK2 pathway is involved in the regulation of cellular adhesion, which is the process by which cells stick together to form tissues and organs. TRAPPC2 is involved in the regulation of the TKTK2 pathway in the regulation of the cytoskeleton, which is the protein structure that organizes the cytoplasm of the cell.

In addition to its role in the TKTK2 pathway, TRAPPC2 is also involved in the regulation of several other signaling pathways. It is involved in the regulation of the Notch signaling pathway, which is involved in the regulation of cellular signaling byNotch proteins. involved in the regulation of the NF-kappa-B signaling pathway, which is involved in the regulation of cellular signaling by nuclear factor kappa B (NFKB).

TRAPPC2 is a potential drug target and biomarker due to its involvement in several diseases, including cancer. Cancer is a disease that is characterized by the uncontrolled growth and proliferation of cells. It is a leading cause of death in the world, and its incidence is increasing due to the increasing number of cases. The TKTK2 pathway is involved in the regulation of cell signaling in cancer, and TRAPPC2 is a key regulator of this pathway. As a potential drug target, TRAPPC2 may be used to treat various types of cancer.

TRAPPC2 is also a potential biomarker for cancer. The TKTK2 pathway is involved in the regulation of cell signaling in cancer, and TRAPPC2 is a key regulator of this pathway. As a potential biomarker, TRAPPC2 may be used to diagnose and

Protein Name: Trafficking Protein Particle Complex Subunit 2

Functions: Prevents transcriptional repression and induction of cell death by ENO1 (By similarity). May play a role in vesicular transport from endoplasmic reticulum to Golgi

The "TRAPPC2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRAPPC2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets